Cargando…
Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study
BACKGROUND: ‘No evidence of disease activity’ (NEDA), a composite measure of clinical and magnetic resonance imaging outcomes, provides a comprehensive assessment of disease activity, but is not extensively reported in clinical practice. NEDA-3 is defined as patients with no new/enlarged T2 or gadol...
Autores principales: | Weinstock-Guttman, Bianca, Medin, Jennie, Khan, Nasreen, Korn, Jonathan R., Lathi, Ellen, Silversteen, Jason, Calkwood, Jonathan, Silva, Diego, Zivadinov, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843701/ https://www.ncbi.nlm.nih.gov/pubmed/29270772 http://dx.doi.org/10.1007/s40263-017-0482-4 |
Ejemplares similares
-
An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MS‐MRIUS Study
por: Zivadinov, Robert, et al.
Publicado: (2016) -
Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients()
por: Graziano, Elliot, et al.
Publicado: (2015) -
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015) -
Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018) -
Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)